MET and non-small cell lung carcinoma: Notably, capmatinib demonstrated a profound intracranial response in a crizotinib-resistant brain lesion of an advanced NSCLC patient with the same MET exon 14 skipping mutation, suggesting superior central nervous system penetration and effectiveness in treating brain metastases [80].